Green Growth mulls takeover bid for Canadian cannabis company Aphria thumbnail

Green Growth mulls takeover bid for Canadian cannabis company Aphria

CNBC’s Aditi Roy discusses Green Growth’s takeover bid of Canadian cannabis company Aphria following the country’s legalization of marijuana this year. Subscribe to CNBC: About CNBC: From ‘Wall Street’ to…

ETF Spotlight: Aurora cannabis hit by pandemic-related restrictions thumbnail

ETF Spotlight: Aurora cannabis hit by pandemic-related restrictions

CNBC’s Morgan Brennan takes a look at cannabis-focused ETFs and the dip in Aurora shares. For access to live and exclusive video from CNBC subscribe to CNBC PRO: Subscribe to…

How illegal dispensaries are a threat to the legal cannabis industry thumbnail

How illegal dispensaries are a threat to the legal cannabis industry

The booming business of cannabis is what many investors are calling the new gold rush. But with those potential riches comes this reality: there’s a much bigger boom in the…

U.S. vs. Canadian cannabis stocks: Key distinctions thumbnail

U.S. vs. Canadian cannabis stocks: Key distinctions

Tim Seymour, who runs the Amplify Seymour Cannabis ETF (CNBS), explains the performance discrepancy between U.S. and Canadian pot stocks around U.S. elections. For access to live and exclusive video…

Canopy Growth CEO on cannabis sell-off thumbnail

Canopy Growth CEO on cannabis sell-off

Bruce Linton, Canopy Growth CEO, discusses the volatile moves in cannabis stocks just a week after Canada legalized recreational marijuana use.

Hexo needs strategic options to compete in cannabis industry: Activist investor thumbnail

Hexo needs strategic options to compete in cannabis industry: Activist investor

Activist investor and Riposte Managing Partner Khaled Beydoun explains why he believes Canadian cannabis company Hexo can go higher.

GW Pharmaceuticals CEO: ‘Real Science’ in Cannabis | Mad Money | CNBC thumbnail

GW Pharmaceuticals CEO: ‘Real Science’ in Cannabis | Mad Money | CNBC

Canada’s marijuana legalization may be all the rage, but one drug company has been working for years to create real cannabis-based medicine. Jim Cramer hears from GW Pharma’s CEO about…

US Officials could be ready to crack down on cannabis craze thumbnail

US Officials could be ready to crack down on cannabis craze

Are US border officials cracking down on the cannabis industry? Pot stocks get smoked. With CNBC’s Aditi Roy and Scott Wapner, and the Fast Money traders, Pete Najarian, Tim Seymour,…

How midterm elections could impact the cannabis business thumbnail

How midterm elections could impact the cannabis business

Vivien Azer, Cowen senior research analyst, and CNBC’s Aditi Roy join ‘Squawk Alley’ to discuss how cannabis regulation could be affected by the midterm elections, specifically in Utah, North Dakota,…

Inside one of the biggest cannabis investor conferences thumbnail

Inside one of the biggest cannabis investor conferences

The cannabis buzz. Is regulation a catalyst for pot stocks? Is it time to buy? With FM trader Tim Seymour, CNBC’s Melissa Lee and the Fast Money traders, Dan Nathan,…